BambooPanda
$PLX Bit late, been busy.
My take on Q3 earnings:
- As expected on Q2 highest finished goods Q3 revenues were higher than Q2.
- Q3 finished goods at a new record high of 20.8M, 16% higher than Q2's 17.9M which was itself 17% higher than Q1's 15.4M, which as 48% higher than the 10.4M from Q4 2025.
Logic would submit Zack's Q4 earnings are wrong and we should see Q4 revenues higher than Q3.
- Management said uptake is accelerating in all geographies particularly EU with E4W.
- Brazil, high Fabry population, approved both regimens at the same time.
- Management increased total Fabry market capture to 25%
- mentioned management expects moving to next tier royalty within 6 months, I assume means to 20%.
3.2B*25% market = 800M*20% royalty = 160M to PLX
And by 2031 one might expect at least 25% royalty = 200M to PLX
With baseline 15x royalty revenue multiple = MC of 2.4B to 3B
This does not include potential positive PRX-115 Phase 3/approval by then too.
Excellent.
15

:format(webp)/https%3A%2F%2Fmma.prnewswire.com%2Fmedia%2F999479%2FProtalix_Biotherapeutics_Logo.jpg%3Fp%3Dfacebook)